No Data
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $6
Taysha Gene Therapies To Present Biodistribution Data From An Analysis Evaluating AAV9 Gene Therapy Delivery At The Upcoming 31st Annual ESGCT Congress
Taysha Gene Therapies (TSHA) Upgraded to Strong Buy: Here's Why
Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?
Express News | Taysha Gene Therapies Announces Oral Presentation on Tsha-102 in Rett Syndrome at Upcoming 9TH World Rett Syndrome Congress
Truist Financial Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Taysha Gene Therapies(TSHA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.4% and a total average return of 20.8%